Avelumab

Generic Name
Avelumab
Brand Names
Bavencio
Drug Type
Biotech
Chemical Formula
-
CAS Number
1537032-82-8
Unique Ingredient Identifier
KXG2PJ551I
Background

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...

Indication

Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...

Associated Conditions
Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
Associated Therapies
First Line Chemotherapy, Maintenance therapy

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

First Posted Date
2022-02-21
Last Posted Date
2023-05-03
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
1
Registration Number
NCT05249569
Locations
🇺🇸

The University of Texas Southwestern Medical Center, Dallas, Texas, United States

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1

First Posted Date
2022-02-03
Last Posted Date
2024-03-19
Lead Sponsor
TILT Biotherapeutics Ltd.
Target Recruit Count
15
Registration Number
NCT05222932
Locations
🇫🇮

Docrates Cancer Center, Helsinki, Finland

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

First Posted Date
2022-02-01
Last Posted Date
2023-11-14
Lead Sponsor
Ludwig-Maximilians - University of Munich
Target Recruit Count
57
Registration Number
NCT05217069
Locations
🇩🇪

Ludwig Maximilians University, Munich, Germany

Avelumab, Palbociclib and Axitinib in Advanced RCC

First Posted Date
2022-01-04
Last Posted Date
2023-09-07
Lead Sponsor
Bradley A. McGregor, MD
Registration Number
NCT05176288

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-10-18
Last Posted Date
2024-10-01
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Target Recruit Count
50
Registration Number
NCT05081180
Locations
🇨🇦

CHU Sainte-Justine, Montréal, Canada

🇨🇦

The Hospital for Sick Children, Toronto, Canada

🇫🇷

CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique, Angers Cedex 9, France

and more 6 locations

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

First Posted Date
2021-09-28
Last Posted Date
2024-11-13
Lead Sponsor
Pfizer
Target Recruit Count
67
Registration Number
NCT05059522
Locations
🇺🇸

Highlands Oncology Group, PA, Springdale, Arkansas, United States

🇷🇺

Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation

🇺🇸

MSK Monmouth, Middletown, New Jersey, United States

and more 66 locations

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Completed
Conditions
Interventions
First Posted Date
2021-08-19
Last Posted Date
2023-12-06
Lead Sponsor
Pfizer
Target Recruit Count
48
Registration Number
NCT05012865
Locations
🇯🇵

Osaka University Hospital, Suita-city, Osaka, Japan

🇯🇵

Jichi Medical University Saitama Medical Center, Saitama City, Saitama, Japan

🇯🇵

Kurume University Hospital, Kurume, Fukuoka, Japan

and more 9 locations

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

First Posted Date
2021-05-14
Last Posted Date
2024-03-22
Lead Sponsor
G1 Therapeutics, Inc.
Target Recruit Count
92
Registration Number
NCT04887831
Locations
🇺🇸

Tennessee Oncology, PLLC, Nashville, Tennessee, United States

🇺🇸

Beacon Cancer Center PLLC, Coeur d'Alene, Idaho, United States

🇫🇷

Institut Bergonié - Oncologie Médicale et Pédiatrique, Bordeaux cedex, Gironde, France

and more 31 locations
© Copyright 2024. All Rights Reserved by MedPath